Selected research
Market Structure
Global Transdermal Testosterone Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Transdermal Testosterone market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Transdermal Testosterone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Transdermal Testosterone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Transdermal Testosterone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Transdermal Testosterone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Transdermal Testosterone include Teva, AbbVie, Upsher-Smith Laboratories, Perrigo, Lupin, Endo Pharmaceuticals, Dr. Reddy's Laboratories, Cipla Inc. and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Transdermal Testosterone market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Transdermal Testosterone and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Transdermal Testosterone sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Transdermal Testosterone market size, projected growth trends, production technologies, key applications, and end-use industries.
Transdermal Testosterone Segment by Company
Teva
AbbVie
Upsher-Smith Laboratories
Perrigo
Lupin
Endo Pharmaceuticals
Dr. Reddy's Laboratories
Cipla Inc.
Allergan
Acerus Pharmaceuticals
Transdermal Testosterone Segment by Type
Gel
Patch
Transdermal Testosterone Segment by Application
Late-Onset Hypogonadism
Hypogonadotropic Hypogonadism
Primary Hypogonadism
Transdermal Testosterone Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Testosterone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Testosterone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Testosterone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Transdermal Testosterone market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transdermal Testosterone manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Transdermal Testosterone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Transdermal Testosterone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Gel
- Patch
Applications
- Late-Onset Hypogonadism
- Hypogonadotropic Hypogonadism
- Primary Hypogonadism
Companies covered
- Teva
- AbbVie
- Upsher-Smith Laboratories
- Perrigo
- Lupin
- Endo Pharmaceuticals
- Dr. Reddy's Laboratories
- Cipla Inc.
- Allergan
- Acerus Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Transdermal Testosterone Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Transdermal Testosterone Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Transdermal Testosterone Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Transdermal Testosterone Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Transdermal Testosterone Market Dynamics
- 2.1 Transdermal Testosterone Industry Trends
- 2.2 Transdermal Testosterone Industry Drivers
- 2.3 Transdermal Testosterone Industry Opportunities and Challenges
- 2.4 Transdermal Testosterone Industry Restraints
3 Transdermal Testosterone Market by Manufacturers
- 3.1 Global Transdermal Testosterone Revenue by Manufacturers (2021-2026)
- 3.2 Global Transdermal Testosterone Sales by Manufacturers (2021-2026)
- 3.3 Global Transdermal Testosterone Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Transdermal Testosterone Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Transdermal Testosterone Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Transdermal Testosterone Manufacturers, Product Type & Application
- 3.7 Global Transdermal Testosterone Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Transdermal Testosterone Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Transdermal Testosterone Players Market Share by Revenue in 2025
- 3.8.3 2025 Transdermal Testosterone Tier 1, Tier 2, and Tier 3
4 Transdermal Testosterone Market by Type
- 4.1 Transdermal Testosterone Type Introduction
- 4.1.1 Gel
- 4.1.2 Patch
- 4.2 Global Transdermal Testosterone Sales by Type
- 4.2.1 Global Transdermal Testosterone Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Transdermal Testosterone Sales by Type (2021-2032)
- 4.2.3 Global Transdermal Testosterone Sales Market Share by Type (2021-2032)
- 4.3 Global Transdermal Testosterone Revenue by Type
- 4.3.1 Global Transdermal Testosterone Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Transdermal Testosterone Revenue by Type (2021-2032)
- 4.3.3 Global Transdermal Testosterone Revenue Market Share by Type (2021-2032)
5 Transdermal Testosterone Market by Application
- 5.1 Transdermal Testosterone Application Introduction
- 5.1.1 Late-Onset Hypogonadism
- 5.1.2 Hypogonadotropic Hypogonadism
- 5.1.3 Primary Hypogonadism
- 5.2 Global Transdermal Testosterone Sales by Application
- 5.2.1 Global Transdermal Testosterone Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Transdermal Testosterone Sales by Application (2021-2032)
- 5.2.3 Global Transdermal Testosterone Sales Market Share by Application (2021-2032)
- 5.3 Global Transdermal Testosterone Revenue by Application
- 5.3.1 Global Transdermal Testosterone Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Transdermal Testosterone Revenue by Application (2021-2032)
- 5.3.3 Global Transdermal Testosterone Revenue Market Share by Application (2021-2032)
6 Global Transdermal Testosterone Sales by Region
- 6.1 Global Transdermal Testosterone Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Transdermal Testosterone Sales by Region (2021-2032)
- 6.2.1 Global Transdermal Testosterone Sales by Region (2021-2026)
- 6.2.2 Global Transdermal Testosterone Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Transdermal Testosterone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Transdermal Testosterone Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Transdermal Testosterone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Transdermal Testosterone Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Transdermal Testosterone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Transdermal Testosterone Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Transdermal Testosterone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Transdermal Testosterone Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Transdermal Testosterone Revenue by Region
- 7.1 Global Transdermal Testosterone Revenue by Region
- 7.1.1 Global Transdermal Testosterone Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Transdermal Testosterone Revenue by Region (2021-2026)
- 7.1.3 Global Transdermal Testosterone Revenue by Region (2027-2032)
- 7.1.4 Global Transdermal Testosterone Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Transdermal Testosterone Revenue (2021-2032)
- 7.2.2 North America Transdermal Testosterone Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Transdermal Testosterone Revenue (2021-2032)
- 7.3.2 Europe Transdermal Testosterone Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Transdermal Testosterone Revenue (2021-2032)
- 7.4.2 Asia-Pacific Transdermal Testosterone Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Transdermal Testosterone Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Transdermal Testosterone Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva
- 8.1.1 Teva Company Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Transdermal Testosterone Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 AbbVie
- 8.2.1 AbbVie Company Information
- 8.2.2 AbbVie Business Overview
- 8.2.3 AbbVie Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 AbbVie Transdermal Testosterone Product Portfolio
- 8.2.5 AbbVie Recent Developments
- 8.3 Upsher-Smith Laboratories
- 8.3.1 Upsher-Smith Laboratories Company Information
- 8.3.2 Upsher-Smith Laboratories Business Overview
- 8.3.3 Upsher-Smith Laboratories Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Upsher-Smith Laboratories Transdermal Testosterone Product Portfolio
- 8.3.5 Upsher-Smith Laboratories Recent Developments
- 8.4 Perrigo
- 8.4.1 Perrigo Company Information
- 8.4.2 Perrigo Business Overview
- 8.4.3 Perrigo Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Perrigo Transdermal Testosterone Product Portfolio
- 8.4.5 Perrigo Recent Developments
- 8.5 Lupin
- 8.5.1 Lupin Company Information
- 8.5.2 Lupin Business Overview
- 8.5.3 Lupin Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Lupin Transdermal Testosterone Product Portfolio
- 8.5.5 Lupin Recent Developments
- 8.6 Endo Pharmaceuticals
- 8.6.1 Endo Pharmaceuticals Company Information
- 8.6.2 Endo Pharmaceuticals Business Overview
- 8.6.3 Endo Pharmaceuticals Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Endo Pharmaceuticals Transdermal Testosterone Product Portfolio
- 8.6.5 Endo Pharmaceuticals Recent Developments
- 8.7 Dr. Reddy's Laboratories
- 8.7.1 Dr. Reddy's Laboratories Company Information
- 8.7.2 Dr. Reddy's Laboratories Business Overview
- 8.7.3 Dr. Reddy's Laboratories Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Dr. Reddy's Laboratories Transdermal Testosterone Product Portfolio
- 8.7.5 Dr. Reddy's Laboratories Recent Developments
- 8.8 Cipla Inc.
- 8.8.1 Cipla Inc. Company Information
- 8.8.2 Cipla Inc. Business Overview
- 8.8.3 Cipla Inc. Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Cipla Inc. Transdermal Testosterone Product Portfolio
- 8.8.5 Cipla Inc. Recent Developments
- 8.9 Allergan
- 8.9.1 Allergan Company Information
- 8.9.2 Allergan Business Overview
- 8.9.3 Allergan Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Allergan Transdermal Testosterone Product Portfolio
- 8.9.5 Allergan Recent Developments
- 8.10 Acerus Pharmaceuticals
- 8.10.1 Acerus Pharmaceuticals Company Information
- 8.10.2 Acerus Pharmaceuticals Business Overview
- 8.10.3 Acerus Pharmaceuticals Transdermal Testosterone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Acerus Pharmaceuticals Transdermal Testosterone Product Portfolio
- 8.10.5 Acerus Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Transdermal Testosterone Value Chain Analysis
- 9.1.1 Transdermal Testosterone Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Transdermal Testosterone Production Mode & Process
- 9.2 Transdermal Testosterone Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Transdermal Testosterone Distributors
- 9.2.3 Transdermal Testosterone Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst